Clinical trial · no report yet · Phase 2
IFM2021-01
Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma
- NCT05572229 ↗
- Active, not recruiting
- University Hospital, Lille
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 8 | |
| X threads | 8 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Study of Teclistamab in Combination With Daratumumab or Lenalidomide in Elderly Patients With Newly Diagnosed Multiple Myeloma
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Teclistamab; Daratumumab; Lenalidomide
- Arms
- Tec-Dara · Experimental
- Tec-Len · Experimental
- Enrollment
- 74 (estimated)
- Primary outcomes
- Rate of very good partial response (VGPR) or better according to the IMWG criteria in patients with newly diagnosed multiple myeloma after 4 cycles of treatment with Tec-Dara or Tec-Len
- Sponsor
- University Hospital, Lille with Janssen Pharmaceutica N.V., Belgium
- Start
- Dec 21, 2023
- Primary completion
- Jun 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05572229 · updated Sep 25, 2026